Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cipla
Merck
Medtronic
Covington
UBS
Citi
QuintilesIMS
Moodys
Argus Health

Generated: January 22, 2018

DrugPatentWatch Database Preview

DUZALLO Drug Profile

« Back to Dashboard

Which patents cover Duzallo, and what generic alternatives are available?

Duzallo is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and seventy-three patent family members in thirty-eight countries.

The generic ingredient in DUZALLO is allopurinol; lesinurad. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the allopurinol; lesinurad profile page.
Summary for DUZALLO
International Patents:173
US Patents:7
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:DUZALLO at DailyMed
Drug patent expirations by year for DUZALLO

US Patents and Regulatory Information for DUZALLO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-001 Aug 18, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-001 Aug 18, 2017 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-001 Aug 18, 2017 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-002 Aug 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-002 Aug 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-002 Aug 18, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-001 Aug 18, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-001 Aug 18, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-001 Aug 18, 2017 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-001 Aug 18, 2017 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for DUZALLO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,344,012 Compounds, compositions and methods of using same for modulating uric acid levels ➤ Subscribe
8,193,234 Compounds, compositions and methods of using same for modulating uric acid levels ➤ Subscribe
7,435,752 N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors ➤ Subscribe
8,552,043 N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors ➤ Subscribe
8,252,828 S-triazolyl .alpha.-mercapto acetanilides as inhibitors of HIV reverse transcriptase ➤ Subscribe
8,173,690 Compounds, compositions and methods of using same for modulating uric acid levels ➤ Subscribe
8,633,232 Compounds, compositions and methods of using same for modulating uric acid levels ➤ Subscribe
8,481,581 S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase ➤ Subscribe
7,683,087 N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl] -p-amino benzoic acids as HIV reverse transcriptase inhibitors ➤ Subscribe
7,947,721 S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for DUZALLO

Supplementary Protection Certificates for DUZALLO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90033-4 Sweden ➤ Subscribe PRODUCT NAME: LESINURAD, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REG. NO/DATE: EU/1/15/1080 20160222
2016 00034 Denmark ➤ Subscribe PRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
169 Luxembourg ➤ Subscribe PRODUCT NAME: LESINURAD , OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION DATE: 20160222
0160027 00203 Estonia ➤ Subscribe PRODUCT NAME: LESINURAAD;REG NO/DATE: EU/1/15/1080 22.02.2016
2016 00034 Denmark ➤ Subscribe PRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
0825 Netherlands ➤ Subscribe PRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222
/2016 Austria ➤ Subscribe PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 (MITTEILUNG) 20160222
2016024,C2135608 Lithuania ➤ Subscribe PRODUCT NAME: LESINURADAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/1080 20160218
2016024 Lithuania ➤ Subscribe PRODUCT NAME: LESINURADAS; REGISTRATION NO/DATE: EU/1/15/1080 20160218
C0031 France ➤ Subscribe PRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Farmers Insurance
Cipla
Federal Trade Commission
Express Scripts
Argus Health
Accenture
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot